Investors
MD Medical Group Today
Investment Case
01
One of the largest private healthcare providers in Russia
02
Leading company focusing on women’s and children’s healthcare
03
A unique combination of a broad scope of medical expertise, extensive geography and varied formats of medical assistance services
04
The first public company in the industry, with the London Stock Exchange IPO back in 2012
05
Primary listing of GDRs on the Moscow Exchange (ticker: MDMG)
Revenue
Rub27.6 bn
for 2023
EBITDA
Rub9.2 bn
for 2023
Profit
up to 100%
may be allocated to dividends
Net cash position
Rub9 bn
as at 31.12.2023
Key Financials
2023 | 2022 | 2021 | 2020 | 2019 | |
Revenue, Rub mln | 27,631 | 25,222 | 25,220 | 19,133 | 16,160 |
EBITDA, Rub mln | 9,218 | 7,924 | 8,276 | 6,008 | 4,635 |
EBITDA margin, % | 33 | 31 | 33 | 31 | 29 |
Net profit, Rub mln | 7,823 | 6,005* | 6,143 | 4,333 | 2,787 |
Net margin, % | 28 | 24 | 24 | 23 | 17 |
CAPEX, Rub mln | 3,580 | 1,169 | 3,790 | 3,904 | 3,992 |
Net debt/EBITDA | -1.0x | -0.5x | 0.2x | 0.5x | 0.8x |
*Adjusted for non-cash items
Annual reports
MD Medical Group Annual Report
PDF
2023
MD Medical Group Annual Report
PDF
2022
MD Medical Group Annual Report
PDF
2021
Share capital structure
Financial results
1Q 2024 Operating Results
PDF
0.3 Mb
FY2023 Financial Results
PDF
409 Kb
3Q 2023 Operating Results
PDF
494 Κb
Corporate Governance
MD Medical adheres to the highest standards of corporate governance. The Company has an effective system of corporate governance and internal control of financial and economic activities that complies with Russian legislation, the rules of the Moscow Exchange, and the best international practices.
Continuous improvement of the corporate governance system is one of the main long-term strategic priorities of the Company.
MoreEvents Calendar
July
31
2Q 2024 Operating results
September
02
1H 2024 Financial results